ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2021. The put-call ratio across all filers is 1.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $56,831 | -82.1% | 57,991 | -71.0% | 0.00% | – |
Q1 2023 | $317,699 | -74.1% | 199,811 | +1.5% | 0.00% | – |
Q4 2022 | $1,227,011 | +7.8% | 196,952 | +16.0% | 0.00% | – |
Q3 2022 | $1,138,000 | +10.5% | 169,826 | +5.0% | 0.00% | – |
Q2 2022 | $1,030,000 | +45.7% | 161,815 | +6.3% | 0.00% | – |
Q1 2022 | $707,000 | +75.0% | 152,209 | +88.7% | 0.00% | – |
Q4 2021 | $404,000 | -50.8% | 80,660 | +18.5% | 0.00% | – |
Q3 2021 | $821,000 | -79.6% | 68,083 | -64.3% | 0.00% | -100.0% |
Q2 2021 | $4,030,000 | -22.8% | 190,497 | +2.3% | 0.00% | -50.0% |
Q1 2021 | $5,223,000 | +10.8% | 186,182 | +2.7% | 0.00% | 0.0% |
Q4 2020 | $4,714,000 | -28.8% | 181,288 | +1.8% | 0.00% | -33.3% |
Q3 2020 | $6,618,000 | -23.8% | 178,025 | +5.2% | 0.00% | -25.0% |
Q2 2020 | $8,682,000 | +49.8% | 169,202 | -7.9% | 0.00% | +33.3% |
Q1 2020 | $5,794,000 | -56.2% | 183,731 | -17.2% | 0.00% | -57.1% |
Q4 2019 | $13,235,000 | +50.0% | 221,952 | -7.8% | 0.01% | +40.0% |
Q3 2019 | $8,824,000 | +0.7% | 240,694 | +27.8% | 0.01% | 0.0% |
Q2 2019 | $8,764,000 | +59.3% | 188,385 | +37.5% | 0.01% | +25.0% |
Q1 2019 | $5,503,000 | -9.4% | 137,042 | +3.8% | 0.00% | -20.0% |
Q4 2018 | $6,071,000 | +1.7% | 131,973 | -1.9% | 0.01% | +25.0% |
Q3 2018 | $5,970,000 | +36.7% | 134,536 | +20.8% | 0.00% | +33.3% |
Q2 2018 | $4,366,000 | -36.8% | 111,389 | +16.7% | 0.00% | -40.0% |
Q1 2018 | $6,904,000 | +15.3% | 95,442 | +4.9% | 0.01% | 0.0% |
Q4 2017 | $5,990,000 | +30.1% | 90,971 | -0.9% | 0.01% | +25.0% |
Q3 2017 | $4,604,000 | +45.7% | 91,843 | +34.5% | 0.00% | +33.3% |
Q2 2017 | $3,160,000 | +62.3% | 68,275 | +23.8% | 0.00% | +50.0% |
Q1 2017 | $1,947,000 | +240.4% | 55,129 | +20.8% | 0.00% | +100.0% |
Q4 2016 | $572,000 | +72.8% | 45,651 | +91.3% | 0.00% | – |
Q3 2016 | $331,000 | -19.3% | 23,864 | -42.4% | 0.00% | -100.0% |
Q2 2016 | $410,000 | -48.0% | 41,444 | -11.0% | 0.00% | 0.0% |
Q1 2016 | $788,000 | -22.3% | 46,550 | +2.2% | 0.00% | 0.0% |
Q4 2015 | $1,014,000 | -2.7% | 45,549 | +3.2% | 0.00% | -50.0% |
Q3 2015 | $1,042,000 | -43.3% | 44,136 | +96.4% | 0.00% | -33.3% |
Q2 2015 | $1,838,000 | +115.7% | 22,470 | +144.2% | 0.00% | +200.0% |
Q1 2015 | $852,000 | +195.8% | 9,200 | +29.6% | 0.00% | – |
Q4 2014 | $288,000 | – | 7,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |